Fund+ leads €23m series-A for Exevir

The round also saw participation from VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices.

With the new funding, Exevir will commit to the international effort to support healthcare systems and to offer new treatment in the fight against Covid-19.

Torsten Mummenbrauer, CEO of ExeVir Bio; Philippe Monteyne, partner at Fund+; Erica Whittaker, head of UCB Ventures; Jérôme Van Biervliet, managing director at VIB; and Katja Rosenkranz, partner at V-Bio will all join the board of Exevir Bio.

Previous funding
Fund+ led the early pre-financing to set up Exevir. The Flemish government and UCB Ventures also participated in the pre-financing.

Company
Exevir Bio, a spinout of VIB, a Belgium-based life sciences research institute, is harnessing its antibody technology platform to generate antiviral therapies providing protection against coronaviruses. The company was founded in 2020 and is headquartered in Ghent.

People
Fund+ – Philippe Monteyne (partner).
VIB – Jérôme Van Biervliet (managing director).
UCB Ventures – Dhaval Patel (chief science officer).
FPIM – Koenraad van Loo (managing director).
Exevir Bio – Torsten Mummenbrauer (CEO).

 

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Early-stage
• Belgium
• Venture